SummaryRMgm-4657
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 31370870 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Yeoh LM, McFadden GI, Ralph SA |
Name Group/Department | Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institut |
Name Institute | The University of Melbourne |
City | Parkville |
Country | Australia |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4657 |
Principal name | PbSR-MG KO |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Normal gametocyte production. Activation of female gametocytes normal. Male exflagellation, however, strongly reduced. Flagella stained with an anti-tubulin antibody remain curled within the gametocyte body. Motility of male free gametes strongly impaired. |
Fertilization and ookinete | Not tested |
Oocyst | Ablation of PbSR-MG also resulted in fewer oocysts per mosquito host. To test if this difference solely reflected the defect in exflagellation, we repeated the mosquito infection using equal numbers of in vitro generated ookinetes. Despite exposing mosquitoes to equal infective load, we still observed a significant difference in oocyst numbers in PbSR-MG KO compared to wild-type parental parasites. |
Sporozoite | Not different from wild type |
Liver stage | Not different from wild type |
Additional remarks phenotype | Mutant/mutation Localizing an integrated, hemagglutinin-tagged (HA-tagged) PbSR-MG confirmed its expected nuclear localization (see mutant RMgm-4658) Phenotype Evidence is presented for the following: |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0921600 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1126800 | ||||||||||||||||||||||||
Gene product | RNA-binding protein, putative | ||||||||||||||||||||||||
Gene product: Alternative name | PbSR-MG | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | Yes | ||||||||||||||||||||||||
Name of PlasmoGEM construct/vector | PbGEM-240478 | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
![]()
| |||||||||||||||||||||||||
top of page |